Tests for comparing mark-specific hazards and cumulative incidence functions

Lifetime Data Analysis

Volumn 10, Issue 1, 2004, Pages 5-28

  Gilbert, Peter B ^a   McKeague, Ian W ^b   Sun, Yanqing ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

Competing risks; Continuous mark; Distribution free tests; Nonparametric statistics; Right censored data

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INCIDENCE; METHODOLOGY; MONTE CARLO METHOD; NONPARAMETRIC TEST; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TREATMENT FAILURE; VIROLOGY;

ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; MONTE CARLO METHOD; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 2942670780     PISSN: 13807870     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:LIDA.0000019253.69537.91     Document Type: Article

References (30)

1. E.-E. Aly, S. C. Kochar, and I. W. McKeague, "Some tests for comparing cumulative incidence functions and cause-specific hazard rates," J. Am. Statist. Assoc. vol. 89 pp. 994-999, 1994.
2. P. K. Andersen, O. Borgan, N. Keiding, and R. Gill, Statistical Models Based on Counting Processes, Springer: New York, 1993.
3. P. J. Bickel and M. J. Wichura, "Convergence criteria for multiparameter stochastic processes and some applications," Ann. Math. Statist. vol. 42 pp. 1656-1670, 1971.
4. Y. Bilias, M. Gu, and Z. Ying, "Towards a general asymptotic theory for Cox model with staggered entry," Ann. Statist. vol. 25 pp. 662-682, 1997.
5. P. Billingsley, Convergence of Probability Measures, Wiley: New York, 1968.
6. R. T. D'Aquila, M. D. Hughes, V. A. Johnson, M. A. Fischl, J.-P. Sommadossi, S. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, M. S. Hirsch, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, "Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection," Ann. Int. Med. vol. 124 pp. 1019-1031, 1996.
7. J. P. Fine, "Analysing competing risks data with transformation models," J. Roy. Statist. Soc. Ser. B vol. 61 pp. 817-830, 1999.
8. P. B. Gilbert, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes, "Virological and regimen termination surrogate endpoints in AIDS clinical trials," J. Am. Med. Assoc. vol. 8 pp. 775-782, 2001a.
9. P. B. Gilbert, G. J. Hanna, V. De Gruttola, J. Martinez-Picado, D. R. Kuritzkes, V. A. Johnson, D. D. Richman, and R. T. D'Aquila, "Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens," AIDS Res. Hum. Retroviruses vol. 16 pp. 1325-1336, 2000.
10. P. B. Gilbert, S. G. Self, M. Rao, A. Naficy, and J. D. Clemens, "Sieve analysis: Methods for assessing how vaccine efficacy depends on genotypic and phenotypic pathogen variation from vaccine trial data," J. Clin. Epidemiol. vol. 54 pp. 68-85, 2001b.
11. H. F. Gunthard, A. J. Leigh-Brown, R. T. D'Aquila, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, and J. K. Wong, "Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary resistance in HIV-1 pol," Virology vol. 259 pp. 154-165, 1999.
12. G. J. Hanna, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, A. J. Leigh-Brown, A. V. Savara, J. D. Hazelwood, and R. T. D'Aquila, "Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine," J. Infect. Dis. vol. 181 pp. 904-911, 2000.
13. M. S. Hirsch, F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman, "Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel," J. Am. Med. Assoc. vol. 283 pp. 2417-2426, 2000.
14. X. S. Hu and W. Y. Tsai, "Linear rank tests for competing risks model," Statist. Sin. vol. 9 pp. 971-983, 1999.
15. Y. Huang and T. A. Louis, "Nonparametric estimation of the joint distribution of survival time and mark variables," Biometrika vol. 85 pp. 785-798, 1998.
16. K. F. Lam, "A class of tests for the equality of k cause-specific hazard rates in a competing risks model," Biometrika vol. 85 pp. 179-188, 1998.
17. A. J. Leigh-Brown, H. G. Gunthard, J. K. Wong, R. T. D'Aquila, V. A. Johnson, D. R. Kuritzkes, and D. D. Richman, "Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy," J. Infect. Dis. vol. 180 pp. 1043-1049, 1999.
18. X. Luo and B. Turnbull, "Comparing two treatments with multiple competing risks endpoints," Statist. Sin. vol. 9 pp. 985-997, 1999.
19. I. W. McKeague, A. M. Nikabadze, and Y. Sun, "An omnibus test for independence of a survival time from a covariate," Ann. Statist. vol. 23 pp. 450-475, 1995.
20. I. W. McKeague and K. J. Utikal, "Identifying nonlinear covariate effects in semimartingale regression models," Probab. Theory Rel. Fields vol. 87 pp. 1-25, 1990.
21. M. Olschewski and M. Schumacher, "Statistical analysis of quality of life in cancer clinical trials," Statist. Med. vol. 9 pp. 749-763, 1990.
22. D. Pollard, Empirical Processes: Theory and Applications, NSF-CBMS Regional Conference Series in Probability and Statistics, 2. Institute of Mathematical Statistics, Hayward, CA, 1990.
23. R. L. Prentice, J. D. Kalbfleisch, A. V. Peterson, N. Flournoy, V. T. Farewell, and N. E. Breslow, "The analysis of failure times in the presence of competing risks," Biometrics vol. 34 pp. 541-554, 1978.
24. G. R. Shorack and J. A. Wellner, Empirical Processes with Applications to Statistics, Wiley: New York, 1986.
25. Y. Sun, "Generalized nonparametric test procedures for comparing multiple cause-specific hazard rates," J. Nonparametr. Statist. vol. 13 pp. 171-207, 2001.
26. Y. Sun and R. C. Tiwari, "Comparing cause-specific hazard rates of a competing risks model with censored data," in Analysis of Censored Data, (H. L. Koul and J. V. Deshpandé, eds.) IMS Lecture Notes-Monograph Series vol. 27 pp. 255-270, 1995.
27. A. A. Tsiatis, "A nonidentifiability aspect of the problem of competing risks," Proc. Nat. Acad. Sci. USA vol. 72 pp. 20-22, 1975.
28. UNAIDS, Report from a Meeting of the WHO-UNAIDS Vaccine Advisory Committee, "Approaches to the development of broadly protective HIV vaccines: Challenges posed by genetic, biological and antigenic variability of HIV-1," AIDS vol. 15 pp. W1-W25, 2001.
29. A. W. Van der Vaart and J. A. Wellner, Weak Convergence and Empirical Processes with Applications to Statistics, Springer: New York, 1996.
30. P. G. Yeni, S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding, "Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel," J. Am. Med. Assoc. vol. 288 pp. 222-235, 2002.